The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Meiji’s COVID Jab Might Miss Initial Plan, but Awaits Real Game Next Year
Meiji Seika Pharma’s Kostaive, a self-amplifying mRNA vaccine for COVID-19, might not be up to expectations for the current fiscal year due to “unscientific information” spread among certain parties, but the outlook for 2025 should be brighter, President Daikichiro Kobayashi…
To read the full story
Related Article
- Meiji Pharma Sues CDP Lawmaker for Defamation over Kostaive
December 26, 2024
- Meiji Seika Pharma “Preparing” to Sue CDP’s Haraguchi
November 5, 2024
- Academic Societies Urge COVID-19 Vaccinations, Deny Kostaive “Shedding”
October 22, 2024
- Ex-Health Minister Gets Kostaive Shot, Warns against “Unscientific Concerns”
October 21, 2024
- Negative Impact of Rumors on Kostaive Is Immense: Meiji Pharma President
October 9, 2024
- Panelists See Legal Issue over Providers’ Refusal of People Vaccinated with Replicon Shot
September 20, 2024
- Japan Approves Meiji’s JN.1-Directed COVID-19 Vaccine
September 13, 2024
BUSINESS
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- Towa Lifts Atomoxetine Shipment Curbs Across All Strengths
December 17, 2025
- Daiichi Sankyo Targets Cancer Cure with IO-ADC Combo Strategy
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…